# A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

> **NCT01690871** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Malignant PEComa (Perivascular Epithelioid Cell Tumors)

## Interventions

- **DRUG:** BEZ235

## Key facts

- **NCT ID:** NCT01690871
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01690871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01690871, "A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01690871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*